Wadsworth Center, New York State Department of Health, Albany, New York, USA.
PLoS One. 2011;6(12):e29199. doi: 10.1371/journal.pone.0029199. Epub 2011 Dec 22.
Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disorder caused by a trinucleotide (CAG)(n) repeat expansion in the coding sequence of the huntingtin gene, and an expanded polyglutamine (>37Q) tract in the protein. This results in misfolding and accumulation of huntingtin protein (htt), formation of neuronal intranuclear and cytoplasmic inclusions, and neuronal dysfunction/degeneration. Single-chain Fv antibodies (scFvs), expressed as intrabodies that bind htt and prevent aggregation, show promise as immunotherapeutics for HD. Intrastriatal delivery of anti-N-terminal htt scFv-C4 using an adeno-associated virus vector (AAV2/1) significantly reduces the size and number of aggregates in HDR6/1 transgenic mice; however, this protective effect diminishes with age and time after injection. We therefore explored enhancing intrabody efficacy via fusions to heterologous functional domains. Proteins containing a PEST motif are often targeted for proteasomal degradation and generally have a short half life. In ST14A cells, fusion of the C-terminal PEST region of mouse ornithine decarboxylase (mODC) to scFv-C4 reduces htt exon 1 protein fragments with 72 glutamine repeats (httex1-72Q) by ~80-90% when compared to scFv-C4 alone. Proteasomal targeting was verified by either scrambling the mODC-PEST motif, or via proteasomal inhibition with epoxomicin. For these constructs, the proteasomal degradation of the scFv intrabody proteins themselves was reduced<25% by the addition of the mODC-PEST motif, with or without antigens. The remaining intrabody levels were amply sufficient to target N-terminal httex1-72Q protein fragment turnover. Critically, scFv-C4-PEST prevents aggregation and toxicity of httex1-72Q fragments at significantly lower doses than scFv-C4. Fusion of the mODC-PEST motif to intrabodies is a valuable general approach to specifically target toxic antigens to the proteasome for degradation.
亨廷顿病(HD)是一种致命的常染色体显性神经退行性疾病,由亨廷顿基因编码序列中的三核苷酸(CAG)(n)重复扩展以及蛋白质中的扩展多聚谷氨酰胺(>37Q)片段引起。这导致亨廷顿蛋白(htt)的错误折叠和积累,形成神经元核内和细胞质内含物,并导致神经元功能障碍/变性。单链 Fv 抗体(scFv)作为与 htt 结合并防止聚集的内抗体表达,作为 HD 的免疫疗法具有很大的希望。使用腺相关病毒载体(AAV2/1)将抗 N 端 htt scFv-C4 递送至纹状体,可显著减少 HDR6/1 转基因小鼠中聚集体的大小和数量;然而,这种保护作用随着时间的推移和注射后时间的推移而减弱。因此,我们通过融合异源功能域来探索增强内体功效。含有 PEST 基序的蛋白质通常被靶向进行蛋白酶体降解,并且通常具有较短的半衰期。在 ST14A 细胞中,与 scFv-C4 相比,将鼠鸟氨酸脱羧酶(mODC)的 C 端 PEST 区融合到 scFv-C4 中可使含有 72 个谷氨酰胺重复的 htt 外显子 1 蛋白片段(httex1-72Q)减少约 80-90%。通过 scFv-C4 单独降解。蛋白酶体靶向通过扰乱 mODC-PEST 基序或用环氧酶素抑制蛋白酶体来验证。对于这些构建体,添加 mODC-PEST 基序可将 scFv 内体蛋白本身的蛋白酶体降解降低<25%,无论是否存在抗原。残留的内体水平足以充分靶向 N 端 httex1-72Q 蛋白片段的周转率。至关重要的是,scFv-C4-PEST 以比 scFv-C4 低得多的剂量防止 httex1-72Q 片段的聚集和毒性。将 mODC-PEST 基序融合到内体中是一种有价值的通用方法,可以将有毒抗原特异性靶向蛋白酶体进行降解。